Latest news for HLS Therapeutics (OTC:HLTRF) Stock

HLS Therapeutics

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, and the United States, and the Rest of the world.

HLS THERAPEUTICS INC by HLS Therapeutics Inc.

HLS Therapeutics Inc

News

Buybacks

Bunge Expands Share Repurchase Program By $500M, Increasing Total Authorization To $1.3B Following Sale Of Sugar And Bioenergy JV Interest; CEO Highlights Commitment To Capital Allocation

Macquarie analyst Paul Golding maintains Live Nation Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>) with a Outperform and raises the price target from $130 to $146.

Price Target

Analyst Ratings

Macquarie Maintains Outperform on Live Nation Entertainment, Raises Price Target to $146

AppTech Payments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APCX#NASDAQ">APCX</a>) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.06) by 33.33 percent. This is a 46.67 percent increase over losses of $(0.15) per share from the same period last year. The company reported $43.00 thousand in sales this quarter. This is a 69.29 percent decrease over sales of $140.00 thousand the same period last year.

Earnings

Earnings Misses

APCX

AppTech Payments Q3 EPS $(0.08) Misses $(0.06) Estimate, Sales $43.00K Down From $140.00K YoY

Cathie Wood, CEO of asset management giant Ark Invest, suggested that Bitcoin&#8217;s (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) price could hit a base target of $650,000 by 2030, with an optimistic scenario reaching <a href="https://www.benzinga.com/money/bitcoin-price-prediction">as high as $1.5 million</a>. 
What Happened: Wood, a long-time Bitcoin proponent who first invested in the digital asset in 2015, attributes the surge in Bitcoin&#8217;s price to two primary factors: regulatory relief on the horizon and Bitcoin's growing distinction from other assets.
In an <a href="https://www.youtube.com/watch?v=RW2cb5KGaTg">interview</a> with CNBC on Friday, Wood said she sees institutional interest in Bitcoin intensifying, with asset allocators increasingly recognizing its unique behavior compared to traditional assets.
Ark Invest, which was the first public asset manager to gain Bitcoin exposure at $250 in 2015, maintains an optimistic outlook for the cryptocurrency's future.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41799045/ark-invests-cathie-wood-joins-call-for-strategic-bitcoin-reserve-gives-thumbs-up-to-cynthi">Ark Invest&#8217;s Cathie Wood Joins Call For Strategic Bitcoin Reserve, Gives Thumbs Up To Cynthia Lummis&#8217; Plan</a>
Wood's prediction ties into Ark Invest's broader outlook, which also includes optimism about the potential for the <a href="https://www.benzinga.com/24/11/41928272/cathie-woods-ark-invest-foresees-crypto-industry-boost-under-incoming-trump-administration">upcoming Donald Trump administration</a> to provide clearer regulations for the cryptocurrency industry in the United States.
With the end of current SEC Chair Gary Gensler&#8216;s term, the firm <a href="https://www.youtube.com/watch?v=RW2cb5KGaTg">anticipates</a> a more crypto-friendly SEC and a shift away from "regulation by enforcement," which could provide the regulatory clarity needed to spur further institutional investment.
What&#8217;s Next: The influence of&nbsp;<a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment" target="_blank" rel="noreferrer noopener">Bitcoin as an institutional asset class</a>&nbsp;is expected to be thoroughly explored at Benzinga&#8217;s upcoming&nbsp;<a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a>&nbsp;event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/global/24/11/41891628/ross-gerber-cathie-wood-or-gary-black-whose-funds-stack-up-against-sp-500s-gains-in-2024">Ross Gerber, Cathie Wood Or Gary Black? Whose Funds Stack Up Against S&amp;P 500&#8217;s Gains In 2024?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin To Hit Up To $1.5 Million By 2030, Says Cathie Wood

<a href="https://pr.report/4a65">Gladstone Commercial Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOD#NASDAQ">GOOD</a>) (the &quot;Company&quot;) announced that Terry Lee Brubaker will be retiring as Chief Operating Officer of the Company effective December 2, 2024. Mr. Brubaker is also retiring as director and executive officer of Gladstone Management Corporation, the Company&#39;s investment adviser, and as a member of the board of managers and an executive officer of Gladstone Administration, LLC, the Company&#39;s administrator, also effective December 2, 2024. Following Mr. Brubaker&#39;s departure, Michael LiCalsi, the Company&#39;s General Counsel and Secretary, who also serves as Gladstone Administration&#39;s President, General Counsel and Secretary, will assume certain additional operational responsibilities while Gladstone Management will conduct a national search for a Chief Investment Officer to fill Mr. Brubaker&#39;s investment committee responsibilities.

Management

GLAD

GOOD

Gladstone Announces Retirement Of COO Terry Lee Brubaker, Effective December 2, 2024; Michael LiCalsi, The Co's General Counsel And Secretary, Who Also Serves As Gladstone Administration's President, General Counsel And Secretary, Will Assume Certain Additional Operational Responsibilities

Insider Trades

Constellation Brands Director Richard Sands Sells 59,637 Shares At Average Price Of $240.38, Totaling $14.34M

LAND

Gladstone Land Announces Retirement Of COO Terry Lee Brubaker

<a href="https://www.globenewswire.com/Tracker?data=BVJO5xwsj0LDrAwUh3f-vBWd8O-_SqCpBG0OQjNTLTl8NV_twYqnXWKH3Tw11TbMrVsZnk_gKCIf66hPIR6PeWqOselKtKA0MlifgOq2mRRbk4p4SQOnMcFhljd8IDlL">Perspective Therapeutics, Inc.</a>&nbsp;("Perspective" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CATX#NYSE">CATX</a>), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today released details regarding the upcoming presentation of initial results from the Company-sponsored Phase 1/2a trial of [212Pb]VMT-α-NET at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium taking place November 21-23, 2024 in Chicago.
The presentation entitled "Preliminary safety and efficacy data of [212Pb]VMT-α-NET in somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors (NETs)" will be presented by Richard L. Wahl, MD, (Professor of Radiology, Mallinckrodt Institute of Radiology at Washington University School of Medicine) on Friday, November 22, 2024 at 9:05 am CT.&nbsp;&nbsp; Results of the study are also available as a poster (number C-37) at the NANETS symposium.

Biotech

General

CATX

Perspective Therapeutics To Discuss Data On [212Pb]VMT-α-NET Presented At The 2024 NANETS Multidisciplinary NET Medical Symposium On November 21, 2024

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4304665-1&amp;h=2441800747&amp;u=http%3A%2F%2Fwww.federalrealty.com%2F&amp;a=Federal+Realty+Investment+Trust">Federal Realty Investment Trust</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRT#NYSE">FRT</a>) announced today that Jeffrey S. Berkes, the Company's President and Chief Operating Officer, will be leaving the company effective December 31, 2024. Don Wood, Federal's Chief Executive Officer, commented, "Jeff has been my trusted partner and good friend here at Federal for the past 24 years and has been instrumental in growing the company and positioning the company as a leader in the industry. He's one of the finest professionals and human beings in our business. I'll surely miss working with him on a daily basis." Mr. Wood will reassume the additional position of President of the Company. The position of Chief Operating Officer will not be backfilled.
Wendy Seher, the Eastern Region President and Chief Operating Officer, a 22-year company veteran, and Jeff Kreshek, the Western Region President and Chief Operating Officer, a 13-year company veteran will continue in their senior operating roles at the Company and report directly to Mr. Wood.

Federal Realty Announces Jeffrey S. Berkes, The Company's President And Chief Operating Officer, Will Be Leaving The Company Effective December 31, 2024; Don Wood Will Reassume The Additional Position Of President Of The Company. The Position Of Chief Operating Officer Will Not Be Backfilled.

ADVM

Adverum Biotechnologies Schedules Webcast For November 18 To Present 52-Week LUNA Phase 2 And 4-Year OPTIC Clinical Data, Along With Key Pivotal Program Design

Flux Power Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLUX#NASDAQ">FLUX</a>), a developer of advanced lithium-ion energy storage solutions for electrification of commercial and industrial equipment, today provided an update regarding its previously discussed restatement process and subsequent SEC filings for the fiscal fourth quarter and year ended June 30, 2024, and the fiscal first quarter ended September 30, 2024.
On September 5, 2024, Flux announced that it had identified approximately $1.7 million of excess and obsolete inventory primarily related to product innovation and design of its products during a period of rapid growth over the last several years. A further detailed review of this and related items has resulted in estimated noncash inventory write-downs of approximately $4.4 million and related noncash warranty related items of approximately $0.5 million, totaling adjustments of approximately $4.9 million. This impact is not a one-time adjustment but impacting multiple quarters over multiple years. To properly reflect the obsolete inventory, the Company is currently in the process of restating previously issued financial statements for fiscal year 2023 and the interim periods of fiscal year 2024, which will be reflected in the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2024. The Flux team has completed its internal review of the restatements and 10-K and is working with its auditors to file them as soon as practicable, which reflects a large body of work over an extended period of time. Upon completion, Flux will work to complete the 10-Q filing for the quarter ending September 30, 2024.

FLUX

Flux Identifies $4.9M In Noncash Adjustments For Obsolete Inventory And Warranty Items, Plans To Restate FY23 And FY24 Financials; 10-K And 10-Q Filings Pending Auditor Review

Lakeside Holding Limited Q1 Total Revenues $4,148,476, Down 1.6% YoY, EPS $(0.18) vs $(0.05) YoY

<h3>Gainers</h3>
<ul>
<li>Legacy Education (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LGCY#AMEX">LGCY</a>) shares moved upwards by 23.0% to $6.89 during Friday's pre-market session. The market value of their outstanding shares is at $78.3 million. The company's, Q1 earnings came out yesterday. </li>
<li>TCTM Kids IT Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCTM#NASDAQ">TCTM</a>) shares rose 19.37% to $0.96. The market value of their outstanding shares is at $9.4 million. </li>
<li>Despegar.com (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DESP#NYSE">DESP</a>) stock rose 10.96% to $16.49. The company's market cap stands at $1.1 billion. As per the press release, Q3 earnings came out yesterday. </li>
<li>Allurion Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALUR#NYSE">ALUR</a>) shares rose 7.62% to $0.43. The market value of their outstanding shares is at $27.7 million. As per the news, the Q3 earnings report came out 2 days ago. </li>
<li>Nerdy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRDY#NYSE">NRDY</a>) stock increased by 7.09% to $0.9. The company's market cap stands at $103.9 million. </li>
<li>WeRide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRD#NASDAQ">WRD</a>) shares increased by 6.98% to $16.89. The company's market cap stands at $4.6 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Digital Brands Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBGI#NASDAQ">DBGI</a>) stock decreased by 22.8% to $0.1 during Friday's pre-market session. The market value of their outstanding shares is at $1.0 million. The company's, Q3 earnings came out yesterday. </li>
<li>SRIVARU Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVMH#NASDAQ">SVMH</a>) shares decreased by 17.15% to $0.02. The market value of their outstanding shares is at $10.2 million. </li>
<li>Jianzhi Education Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JZ#NASDAQ">JZ</a>) stock declined by 12.0% to $1.1. The company's market cap stands at $22.2 million. </li>
<li>Destination XL Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXLG#NASDAQ">DXLG</a>) stock decreased by 8.67% to $2.74. The market value of their outstanding shares is at $159.6 million. </li>
<li>Massimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAMO#NASDAQ">MAMO</a>) shares decreased by 8.66% to $3.8. The company's market cap stands at $157.0 million. </li>
<li>Boqii Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BQ#AMEX">BQ</a>) stock declined by 8.55% to $0.44. The company's market cap stands at $2.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ALUR

DBGI

DESP

DXLG

LGCY

MAMO

NRDY

SVMH

TCTM

12 Consumer Discretionary Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>CERo Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) stock increased by 71.0% to $0.32 during Friday's pre-market session. The company's market cap stands at $48.1 million. </li>
<li>QT Imaging Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTI#NASDAQ">QTI</a>) shares moved upwards by 18.58% to $0.58. The company's market cap stands at $12.4 million. As per the news, the Q3 earnings report came out 2 days ago. </li>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) shares rose 18.02% to $0.77. </li>
<li>Alpha Teknova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKNO#NASDAQ">TKNO</a>) stock rose 14.17% to $7.49. The market value of their outstanding shares is at $399.2 million. </li>
<li>Gain Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GANX#NASDAQ">GANX</a>) shares rose 14.04% to $1.99. The market value of their outstanding shares is at $50.8 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) stock increased by 14.02% to $4.96. The market value of their outstanding shares is at $4.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>TFF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TFFP#NASDAQ">TFFP</a>) shares fell 71.9% to $0.45 during Friday's pre-market session. The market value of their outstanding shares is at $1.5 million. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) shares decreased by 60.02% to $0.14. The market value of their outstanding shares is at $11.6 million. As per the news, the Q3 earnings report came out 3 days ago. </li>
<li>Akoya Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKYA#NASDAQ">AKYA</a>) stock declined by 31.31% to $2.15. The market value of their outstanding shares is at $106.4 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) shares declined by 20.85% to $0.76. The market value of their outstanding shares is at $2.8 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) shares declined by 17.66% to $0.3. The company's market cap stands at $1.8 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Carmell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) shares decreased by 13.44% to $0.24. The company's market cap stands at $5.1 million. As per the news, the Q3 earnings report came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKYA

CERO

CTCX

EYEN

GANX

ALPS ETF Trusthen & Steers Global Realty Majors ETF

ISPC

TCBP

TFFP

TIVC

TKNO

12 Health Care Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Simpple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPPL#NASDAQ">SPPL</a>) stock moved upwards by 42.7% to $1.26 during Friday's pre-market session. The company's market cap stands at $20.4 million. </li>
<li>Solidion Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STI#NASDAQ">STI</a>) stock increased by 25.62% to $0.44. The market value of their outstanding shares is at $40.7 million. </li>
<li>1847 Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/EFSH#AMEX">EFSH</a>) shares rose 19.22% to $0.57. </li>
<li>FuelCell Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCEL#NASDAQ">FCEL</a>) shares moved upwards by 18.4% to $8.3. The market value of their outstanding shares is at $169.1 million. </li>
<li>Aqua Metals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQMS#NASDAQ">AQMS</a>) shares rose 12.04% to $2.14. The market value of their outstanding shares is at $14.6 million. The company's, Q3 earnings came out yesterday. </li>
<li>HUHUTECH International Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUHU#NASDAQ">HUHU</a>) shares rose 6.66% to $4.8. The market value of their outstanding shares is at $101.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>iPower (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPW#NASDAQ">IPW</a>) stock declined by 25.0% to $0.9 during Friday's pre-market session. The company's market cap stands at $28.2 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Expion360 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPON#NASDAQ">XPON</a>) shares decreased by 19.72% to $2.77. The company's market cap stands at $1.5 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Microvast Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVST#NASDAQ">MVST</a>) stock fell 14.81% to $0.66. The company's market cap stands at $210.0 million. As per the news, the Q3 earnings report came out 3 days ago. </li>
<li>Fusion Fuel Green (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTOO#NASDAQ">HTOO</a>) stock fell 14.7% to $0.43. The company's market cap stands at $8.4 million. </li>
<li>AgEagle Aerial Sys (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UAVS#AMEX">UAVS</a>) shares fell 13.41% to $3.1. The market value of their outstanding shares is at $2.6 million. </li>
<li>Primech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMEC#NASDAQ">PMEC</a>) shares declined by 12.63% to $0.69. The company's market cap stands at $26.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AQMS

EFSH

FCEL

HTOO

HUHU

MVST

PMEC

SPPL

UAVS

XPON

12 Industrials Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Greenidge Generation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GREE#NASDAQ">GREE</a>) shares rose 55.8% to $3.85 during Friday's pre-market session. The market value of their outstanding shares is at $42.9 million. </li>
<li>Greenidge Generation Holdings Inc. - 8.50% Senior Notes due 2026 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GREEL#NASDAQ">GREEL</a>) stock increased by 15.78% to $11.0. </li>
<li>Red Cat Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCAT#NASDAQ">RCAT</a>) shares moved upwards by 15.42% to $4.64. The market value of their outstanding shares is at $349.8 million. </li>
<li>Brand Engagement Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNAI#NASDAQ">BNAI</a>) shares moved upwards by 15.08% to $0.83. The company's market cap stands at $31.5 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Zeta Global Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>) shares increased by 14.85% to $19.95. The company's market cap stands at $4.7 billion. The company's, Q3 earnings came out 4 days ago. </li>
<li>Abits Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABTS#NASDAQ">ABTS</a>) shares moved upwards by 12.76% to $0.6. The market value of their outstanding shares is at $21.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Quantum Computing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) shares declined by 33.4% to $2.93 during Friday's pre-market session. The market value of their outstanding shares is at $290.3 million. </li>
<li>Wellchange Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WCT#NASDAQ">WCT</a>) shares fell 13.97% to $3.57. The market value of their outstanding shares is at $75.9 million. </li>
<li>FOXO Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/FOXO#AMEX">FOXO</a>) stock decreased by 12.99% to $0.58. The company's market cap stands at $7.9 million. </li>
<li>Mercurity Fintech Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFH#NASDAQ">MFH</a>) shares decreased by 10.09% to $3.21. The company's market cap stands at $195.2 million. </li>
<li>Applied Mat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) stock fell 9.5% to $168.34. The market value of their outstanding shares is at $139.3 billion. As per the press release, Q4 earnings came out yesterday. </li>
<li>Nano Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NA#NASDAQ">NA</a>) shares fell 8.1% to $4.2. The company's market cap stands at $41.2 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABTS

AMAT

BNAI

FOXO

GREE

Greenidge Generation Holdings Inc. - 8.50% Senior Notes due 2026

GREEL

QUBT

RCAT

ZETA

12 Information Technology Stocks Moving In Friday's Pre-Market Session

Offerings

BTCT

BTC Digital Issued 727,425 Shares Via Cashless Exercises In Response To Notices On November 13; Announced An Additional 120,372 Shares Issued On November 15 After Further Exercise Notices

Ratings for Oracle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) were provided by 30 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">14</td>
<td align="right">9</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">6</td>
<td align="right">11</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $178.53, with a high estimate of $205.00 and a low estimate of $140.00. Witnessing a positive shift, the current average has risen by 10.03% from the previous average price target of $162.25.
<img src="https://www.benzinga.com/files/images/story/2024/1731704548_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Oracle among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Ader</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Alex Zukin</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Sector Perform</td>
<td>$165.00</td>
<td>-</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$205.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Mark Moerdler</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$202.00</td>
<td>$201.00</td>
</tr>
<tr>
<td>Brent Thill</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Mark Murphy</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$140.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Karl Keirstead</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Jason Ader</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$190.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Brad Sills</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$195.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$202.00</td>
<td>$172.00</td>
</tr>
<tr>
<td>Derrick Wood</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$175.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Kirk Materne</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$190.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>John Difucci</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$185.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$157.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Announces</td>
<td>Market Outperform</td>
<td>$175.00</td>
<td>-</td>
</tr>
<tr>
<td>Brent Thill</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$170.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Keith Bachman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$173.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Brad Reback</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$155.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Jason Ader</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$175.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$172.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$140.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Siti Panigrahi</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$185.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Karl Keirstead</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$175.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Kirk Materne</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$175.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Derrick Wood</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$180.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Keith Weiss</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$145.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Brad Sills</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$175.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$175.00</td>
<td>$150.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Oracle. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Oracle compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Oracle's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Oracle's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ORCL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Oracle analyst ratings.</a>
<h2>Delving into Oracle's Background</h2>
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
<h3>Oracle's Financial Performance</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Oracle's remarkable performance in 3 months is evident. As of 31 August, 2024, the company achieved an impressive revenue growth rate of 6.86%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Oracle's net margin excels beyond industry benchmarks, reaching 22.01%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Oracle's ROE excels beyond industry benchmarks, reaching 30.01%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Oracle's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.05%, the company showcases efficient use of assets and strong financial health.
Debt Management: Oracle's debt-to-equity ratio is notably higher than the industry average. With a ratio of 7.81, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ORCL

Expert Outlook: Oracle Through The Eyes Of 30 Analysts

4 analysts have shared their evaluations of Tetra Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTEK#NASDAQ">TTEK</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $51.0, a high estimate of $56.00, and a low estimate of $47.00. This current average reflects an increase of 0.49% from the previous average price target of $50.75. 
<img src="https://www.benzinga.com/files/images/story/2024/1731704532_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Tetra Tech by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sangita Jain</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$49.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Sabahat Khan</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$52.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Andrew Wittmann</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$47.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Sangita Jain</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$56.00</td>
<td>$49.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Tetra Tech. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Tetra Tech compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Tetra Tech's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Tetra Tech's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TTEK/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Tetra Tech analyst ratings.</a>
<h2>Get to Know Tetra Tech Better</h2>
Tetra Tech Inc provides consulting and engineering services for environmental, infrastructure, resource management, energy, and international development markets. It specializes in providing water-related services for public and private clients. It designs infrastructure, facilities, and other structures with complex plans and resource management. Tetra Tech has two reportable segments. Its Government Services Group (GSG) reportable segment primarily includes activities with U.S. government clients (federal, state and local) and activities with development agencies worldwide. Commercial/International Services Group (CIG) reportable segment primarily includes activities with U.S. commercial clients and international clients other than development agencies.
<h3>Tetra Tech: Financial Performance Dissected</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Tetra Tech's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 11.2%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Industrials sector.
Net Margin: Tetra Tech's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.38% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Tetra Tech's ROE stands out, surpassing industry averages. With an impressive ROE of 5.28%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Tetra Tech's ROA stands out, surpassing industry averages. With an impressive ROA of 2.1%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.63, Tetra Tech adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TTEK

The Analyst Landscape: 4 Takes On Tetra Tech

NetEase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTES#NASDAQ">NTES</a>) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for NetEase, presenting an average target of $105.0, a high estimate of $120.00, and a low estimate of $82.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 12.5%. 
<img src="https://www.benzinga.com/files/images/story/2024/1731704501_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A comprehensive examination of how financial experts perceive NetEase is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alicia Yap</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Fawne Jiang</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$105.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Jiong Shao</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$82.00</td>
<td>$104.00</td>
</tr>
<tr>
<td>Eddie Leung</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$120.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>Thomas Chong</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$103.00</td>
<td>$126.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to NetEase. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of NetEase compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into NetEase's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NTES/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on NetEase analyst ratings.</a>
<h2>Discovering NetEase: A Closer Look</h2>
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
<h3>Unraveling the Financial Story of NetEase</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: NetEase's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 6.14%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Communication Services sector.
Net Margin: NetEase's net margin is impressive, surpassing industry averages. With a net margin of 26.52%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 5.24%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): NetEase's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 3.57%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.1, NetEase adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NTES

NetEase Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)

HLS Therapeutics appoints John Hanna as interim CFO

HLS Therapeutics GAAP EPS of -$0.17 misses by $0.04, revenue of $15.86M misses by $5.84M

HLS Therapeutics EPS of -$0.19 beats by $0.04, revenue of $12.5M misses by $7.73M

HLS Therapeutics GAAP EPS of -$0.18, revenue of $14.52M

HLS Therapeutics GAAP EPS of -$0.15 beats by $0.04, revenue of $14.08M misses by $6.42M

HLTRF

Raymond James

Raymond James analyst Rahul Sarugaser maintains HLS Therapeutics (OTC:<a class="ticker" href="https://www.benzinga.com/stock/HLTRF#OTC">HLTRF</a>) with a Market Perform and lowers the price target from $6.5 to $5.

Raymond James Maintains Market Perform on HLS Therapeutics, Lowers Price Target to $5

&nbsp;

<h2>Upgrades</h2>

<ul>
	<li>According to Wolfe Research, the prior rating for The AES Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AES#NYSE">AES</a>) was changed from Peer Perform to Outperform. AES earned $0.31 in the second quarter, compared to $0.25 in the year-ago quarter. The current stock performance of AES shows a 52-week-high of $29.07 and a 52-week-low of $15.21. Moreover, at the end of the last trading period, the closing price was at $24.85.</li>
	<li>According to Morgan Stanley, the prior rating for BP PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>) was changed from Underweight to Equal-Weight. For the second quarter, BP had an EPS of $0.83, compared to year-ago quarter EPS of $1.98. At the moment, the stock has a 52-week-high of $28.49 and a 52-week-low of $14.74. BP closed at $25.34 at the end of the last trading period.</li>
	<li>HSBC upgraded the previous rating for Altice USA Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATUS#NYSE">ATUS</a>) from Hold to Buy. For the second quarter, Altice USA had an EPS of $0.51, compared to year-ago quarter EPS of $0.19. The stock has a 52-week-high of $38.30 and a 52-week-low of $25.08. At the end of the last trading period, Altice USA closed at $29.33.</li>
	<li>Raymond James upgraded the previous rating for Switch Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWCH#NYSE">SWCH</a>) from Outperform to Strong Buy. In the second quarter, Switch showed an EPS of $0.04, compared to $0.06 from the year-ago quarter. At the moment, the stock has a 52-week-high of $21.98 and a 52-week-low of $13.38. Switch closed at $20.31 at the end of the last trading period.</li>
	<li>Cowen &amp; Co. upgraded the previous rating for Adtran Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTN#NASDAQ">ADTN</a>) from Market Perform to Outperform. Adtran earned $0.16 in the second quarter, compared to $0.04 in the year-ago quarter. The stock has a 52-week-high of $22.89 and a 52-week-low of $9.66. At the end of the last trading period, Adtran closed at $21.70.</li>
	<li>For Marathon Oil Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRO#NYSE">MRO</a>), Scotiabank upgraded the previous rating of Sector Perform to Sector Outperform. For the second quarter, Marathon Oil had an EPS of $0.22, compared to year-ago quarter EPS of $0.60. The current stock performance of Marathon Oil shows a 52-week-high of $14.33 and a 52-week-low of $3.73. Moreover, at the end of the last trading period, the closing price was at $11.79.</li>
	<li>For ViacomCBS Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIAC#NASDAQ">VIAC</a>), Deutsche Bank upgraded the previous rating of Sell to Hold. ViacomCBS earned $0.97 in the second quarter, compared to $1.25 in the year-ago quarter. The current stock performance of ViacomCBS shows a 52-week-high of $101.97 and a 52-week-low of $25.61. Moreover, at the end of the last trading period, the closing price was at $41.55.</li>
	<li>UBS upgraded the previous rating for Triumph Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGI#NYSE">TGI</a>) from Neutral to Buy. Triumph Group earned $0.09 in the first quarter, compared to $0.19 in the year-ago quarter. At the moment, the stock has a 52-week-high of $22.71 and a 52-week-low of $5.96. Triumph Group closed at $18.12 at the end of the last trading period.</li>
	<li>Raymond James upgraded the previous rating for Equity Residential (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQR#NYSE">EQR</a>) from Underperform to Market Perform. For the second quarter, Equity Residential had an EPS of $0.72, compared to year-ago quarter EPS of $0.86. At the moment, the stock has a 52-week-high of $85.83 and a 52-week-low of $45.42. Equity Residential closed at $84.62 at the end of the last trading period.</li>
	<li>JP Morgan upgraded the previous rating for Switch Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWCH#NYSE">SWCH</a>) from Neutral to Overweight. For the second quarter, Switch had an EPS of $0.04, compared to year-ago quarter EPS of $0.06. At the moment, the stock has a 52-week-high of $21.98 and a 52-week-low of $13.38. Switch closed at $20.31 at the end of the last trading period.</li>
	<li>For Global Payments Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>), BMO Capital upgraded the previous rating of Market Perform to Outperform. In the second quarter, Global Payments showed an EPS of $2.04, compared to $1.31 from the year-ago quarter. At the moment, the stock has a 52-week-high of $220.81 and a 52-week-low of $153.33. Global Payments closed at $170.30 at the end of the last trading period.</li>
	<li>BMO Capital upgraded the previous rating for International Money Express Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMXI#NASDAQ">IMXI</a>) from Market Perform to Outperform. For the second quarter, International Money had an EPS of $0.39, compared to year-ago quarter EPS of $0.28. At the moment, the stock has a 52-week-high of $18.69 and a 52-week-low of $13.14. International Money closed at $16.62 at the end of the last trading period.</li>
	<li>According to Raymond James, the prior rating for Itron Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRI#NASDAQ">ITRI</a>) was changed from Outperform to Strong Buy. Itron earned $0.28 in the second quarter, compared to $0.03 in the year-ago quarter. The stock has a 52-week-high of $122.31 and a 52-week-low of $53.49. At the end of the last trading period, Itron closed at $71.84.</li>
</ul>

<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings upgrades.</a>

&nbsp;

<h2>Downgrades</h2>

<ul>
	<li>For Thomson Reuters Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRI#NYSE">TRI</a>), Canaccord Genuity downgraded the previous rating of Buy to Hold. In the second quarter, Thomson Reuters showed an EPS of $0.48, compared to $0.44 from the year-ago quarter. The stock has a 52-week-high of $113.11 and a 52-week-low of $69.50. At the end of the last trading period, Thomson Reuters closed at $112.13.</li>
	<li>According to Canaccord Genuity, the prior rating for Neurocrine Biosciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) was changed from Buy to Hold. Neurocrine Biosciences earned $0.63 in the second quarter, compared to $1.42 in the year-ago quarter. The stock has a 52-week-high of $120.87 and a 52-week-low of $86.02. At the end of the last trading period, Neurocrine Biosciences closed at $92.69.</li>
	<li>According to Needham, the prior rating for Cornerstone OnDemand Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSOD#NASDAQ">CSOD</a>) was changed from Buy to Hold. Cornerstone OnDemand earned $0.73 in the second quarter, compared to $0.40 in the year-ago quarter. At the moment, the stock has a 52-week-high of $55.50 and a 52-week-low of $32.99. Cornerstone OnDemand closed at $49.92 at the end of the last trading period.</li>
	<li>According to Cowen &amp; Co., the prior rating for Dicerna Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRNA#NASDAQ">DRNA</a>) was changed from Outperform to Market Perform. For the first quarter, Dicerna Pharmaceuticals had an EPS of $0.39, compared to year-ago quarter EPS of $0.31. The current stock performance of Dicerna Pharmaceuticals shows a 52-week-high of $40.14 and a 52-week-low of $16.50. Moreover, at the end of the last trading period, the closing price was at $37.92.</li>
	<li>JP Morgan downgraded the previous rating for Becton, Dickinson and Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) from Overweight to Neutral. In the third quarter, Becton, Dickinson showed an EPS of $2.74, compared to $2.20 from the year-ago quarter. The current stock performance of Becton, Dickinson shows a 52-week-high of $284.97 and a 52-week-low of $219.50. Moreover, at the end of the last trading period, the closing price was at $243.08.</li>
	<li>According to Deutsche Bank, the prior rating for Cardinal Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) was changed from Buy to Hold. In the fourth quarter, Cardinal Health showed an EPS of $0.77, compared to $1.04 from the year-ago quarter. At the moment, the stock has a 52-week-high of $62.96 and a 52-week-low of $44.65. Cardinal Health closed at $50.57 at the end of the last trading period.</li>
	<li>According to Deutsche Bank, the prior rating for Parker Hannifin Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PH#NYSE">PH</a>) was changed from Buy to Hold. For the fourth quarter, Parker Hannifin had an EPS of $4.38, compared to year-ago quarter EPS of $2.55. The current stock performance of Parker Hannifin shows a 52-week-high of $324.68 and a 52-week-low of $183.02. Moreover, at the end of the last trading period, the closing price was at $300.23.</li>
	<li>Baird downgraded the previous rating for FireEye Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEYE#NASDAQ">FEYE</a>) from Outperform to Neutral. For the second quarter, FireEye had an EPS of $0.09, compared to year-ago quarter EPS of $0.09. The current stock performance of FireEye shows a 52-week-high of $25.53 and a 52-week-low of $12.26. Moreover, at the end of the last trading period, the closing price was at $20.09.</li>
	<li>Baird downgraded the previous rating for Itron Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRI#NASDAQ">ITRI</a>) from Outperform to Neutral. In the second quarter, Itron showed an EPS of $0.28, compared to $0.03 from the year-ago quarter. The stock has a 52-week-high of $122.31 and a 52-week-low of $53.49. At the end of the last trading period, Itron closed at $71.84.</li>
	<li>Baird downgraded the previous rating for Cloudflare Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) from Outperform to Neutral. For the second quarter, Cloudflare had an EPS of $0.02, compared to year-ago quarter EPS of $0.03. The current stock performance of Cloudflare shows a 52-week-high of $122.77 and a 52-week-low of $32.70. Moreover, at the end of the last trading period, the closing price was at $121.46.</li>
	<li>Citigroup downgraded the previous rating for IPG Photonics Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPGP#NASDAQ">IPGP</a>) from Buy to Neutral. IPG Photonics earned $1.29 in the second quarter, compared to $0.91 in the year-ago quarter. The stock has a 52-week-high of $262.55 and a 52-week-low of $149.51. At the end of the last trading period, IPG Photonics closed at $183.62.</li>
	<li>JMP Securities downgraded the previous rating for Expedia Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) from Outperform to Market Perform. Expedia Group earned $1.13 in the second quarter, compared to $4.09 in the year-ago quarter. At the moment, the stock has a 52-week-high of $187.93 and a 52-week-low of $80.50. Expedia Group closed at $161.69 at the end of the last trading period.</li>
	<li>According to Oppenheimer, the prior rating for Moderna Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) was changed from Outperform to Perform. In the second quarter, Moderna showed an EPS of $6.46, compared to $0.31 from the year-ago quarter. The stock has a 52-week-high of $443.99 and a 52-week-low of $54.21. At the end of the last trading period, Moderna closed at $416.26.</li>
	<li>For Kala Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALA#NASDAQ">KALA</a>), JP Morgan downgraded the previous rating of Overweight to Neutral. In the second quarter, Kala Pharmaceuticals showed an EPS of $0.57, compared to $0.42 from the year-ago quarter. The current stock performance of Kala Pharmaceuticals shows a 52-week-high of $9.97 and a 52-week-low of $2.75. Moreover, at the end of the last trading period, the closing price was at $3.18.</li>
	<li>SVB Leerink downgraded the previous rating for Karyopharm Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) from Outperform to Market Perform. For the second quarter, Karyopharm Therapeutics had an EPS of $0.71, compared to year-ago quarter EPS of $0.63. At the moment, the stock has a 52-week-high of $18.00 and a 52-week-low of $5.76. Karyopharm Therapeutics closed at $5.93 at the end of the last trading period.</li>
	<li>Raymond James downgraded the previous rating for Core-Mark Holding Co Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORE#NASDAQ">CORE</a>) from Outperform to Market Perform. In the second quarter, Core-Mark Holding Co showed an EPS of $0.50, compared to $0.52 from the year-ago quarter. The stock has a 52-week-high of $47.84 and a 52-week-low of $26.80. At the end of the last trading period, Core-Mark Holding Co closed at $41.67.</li>
	<li>Piper Sandler downgraded the previous rating for Moderna Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) from Overweight to Neutral. In the second quarter, Moderna showed an EPS of $6.46, compared to $0.31 from the year-ago quarter. The current stock performance of Moderna shows a 52-week-high of $443.99 and a 52-week-low of $54.21. Moreover, at the end of the last trading period, the closing price was at $416.26.</li>
</ul>

<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings downgrades.</a>

&nbsp;

<h2>Initiations</h2>

<ul>
	<li>With a Equal-Weight rating, Morgan Stanley initiated coverage on Rover Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROVR#NASDAQ">ROVR</a>). The price target seems to have been set at $11.00 for Rover Group. &nbsp;Moreover, at the end of the last trading period, the closing price was at $11.81.</li>
	<li>With a Buy rating, Jefferies initiated coverage on Petco Health and Wellness Co Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WOOF#NASDAQ">WOOF</a>). The price target seems to have been set at $24.00 for Petco Health and Wellness. Petco Health and Wellness earned $0.17 in the first quarter. The stock has a 52-week-high of $31.08 and a 52-week-low of $17.86. At the end of the last trading period, Petco Health and Wellness closed at $19.74.</li>
	<li>Jefferies initiated coverage on Hillman Solutions Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLMN#NASDAQ">HLMN</a>) with a Buy rating. The price target for Hillman Solutions is set to $17.00. Hillman Solutions earned $1.82 in the second quarter. Hillman Solutions closed at $12.71 at the end of the last trading period.</li>
	<li>With an Outperform rating, BMO Capital initiated coverage on Victoria&#39;s Secret &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>). The price target seems to have been set at $89.00 for Victoria&#39;s Secret.&nbsp;Victoria&#39;s Secret closed at $58.77 at the end of the last trading period.</li>
	<li>With a Neutral rating, New Street Research initiated coverage on DLocal Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLO#NASDAQ">DLO</a>). The price target seems to have been set at $50.00 for DLocal. At the moment, the stock has a 52-week-high of $57.00 and a 52-week-low of $29.57. DLocal closed at $47.47 at the end of the last trading period.</li>
	<li>With a Buy rating, B. Riley Securities initiated coverage on Minim Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MINM#NASDAQ">MINM</a>). The price target seems to have been set at $4.00 for Minim. At the moment, the stock has a 52-week-high of $5.70 and a 52-week-low of $2.26. Minim closed at $2.36 at the end of the last trading period.</li>
	<li>RBC Capital initiated coverage on Berkshire Hills Bancorp Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHLB#NYSE">BHLB</a>) with a Sector Perform rating. The price target for Berkshire Hills Bancorp is set to $29.00. For the second quarter, Berkshire Hills Bancorp had an EPS of $0.44, compared to year-ago quarter EPS of $0.13. The current stock performance of Berkshire Hills Bancorp shows a 52-week-high of $28.89 and a 52-week-low of $8.55. Moreover, at the end of the last trading period, the closing price was at $27.61.</li>
	<li>Credit Suisse initiated coverage on Generac Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNRC#NYSE">GNRC</a>) with an Outperform rating. The price target for Generac Hldgs is set to $523.00. For the second quarter, Generac Hldgs had an EPS of $2.39, compared to year-ago quarter EPS of $1.40. At the moment, the stock has a 52-week-high of $457.00 and a 52-week-low of $164.24. Generac Hldgs closed at $403.72 at the end of the last trading period.</li>
	<li>Citigroup initiated coverage on Progress Software Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRGS#NASDAQ">PRGS</a>) with a Neutral rating. The price target for Progress Software is set to $48.00. Progress Software earned $0.82 in the second quarter, compared to $0.63 in the year-ago quarter. At the moment, the stock has a 52-week-high of $49.23 and a 52-week-low of $34.40. Progress Software closed at $45.71 at the end of the last trading period.</li>
	<li>Goldman Sachs initiated coverage on Dynavax Technologies Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) with a Buy rating. The price target for Dynavax Technologies is set to $19.00. Dynavax Technologies earned $0.06 in the second quarter, compared to $0.53 in the year-ago quarter. The current stock performance of Dynavax Technologies shows a 52-week-high of $11.84 and a 52-week-low of $3.58. Moreover, at the end of the last trading period, the closing price was at $10.33.</li>
</ul>

<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings initiations.</a>

Upgrades

Downgrades

Initiation

Intraday Update

ADTN

ATUS

BHLB

BPMP

COLD

CORE

CSOD

DRNA

DVAX

EXPE

FEYE

GNRC

HLMN

IMXI

IPGP

ISMAY

ITRI

KALA

KPTI

LESL

MINM

MRNA

NBIX

NCAUF

OCFC

PRGS

ROVR

SDXAY

SWCH

VIAC

VSCO

WOOF

Benzinga's Top Ratings Upgrades, Downgrades For August 6, 2021

Raymond James downgrades HLS Therapeutics (OTC:<a class="ticker" href="https://www.benzinga.com/stock/HLTRF#OTC">HLTRF</a>) from Outperform to Market Perform.

Raymond James Downgrades HLS Therapeutics to Market Perform

Comments

HLS Therapeutics

News

Latest news for HLS Therapeutics (OTC:HLTRF) Stock

Monday, March 18, 2024

Friday, August 06, 2021

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga